Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3-month extension study.

Muresanu DF, Alvarez XA, Moessler H, Novak PH, Stan A, Buzoianu A, Bajenaru O, Popescu BO

Journal of the neurological sciences1 Dec 2010Cited by 17 (Europe PMC)

PMID20923712DOI10.1016/j.jns.2010.08.040PepBankPUB-20923712

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

3 results from studies that gave the peptide. 3 results from people.

01HumanRandomized controlled trialEfficacy outcome
In vascular dementia patients, Cerebrolysin 10 mL improved cognitive performance versus placebo at week 16 (p<0.05).
In plain wordsIn vascular dementia patients, Cerebrolysin 10 mL improved cognitive performance compared with placebo at week 16.
Peptide
Cerebrolysin
Outcome
IncreaseADAS-cog+ cognitive performance at week 16
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
10 mL · intravenous · 4 weeksAs given in this study (human).
Measurements
p value for ADAS-cog+ cognitive performance comparison
< 0.05
Cerebrolysin 10 mL versus placebo, week 16
Source sentences
Summary
At the week 16 follow-up visit, Cerebrolysin improved (p<0.05) cognitive performance at the 10-mL and 30-mL doses and reduced qEEG slowing significantly (p<0.05) at the 30-mL dose with respect to the placebo.
3 context sentences(design, population, supporting numbers)
Summary · context
The mean change in score from baseline in the ADAS-cog+ and the slow-to-fast qEEG power ratio (PR), used as an index of qEEG slowing, were the two primary endpoints.
Summary · context
The maintenance of the effects of Cerebrolysin, a peptidergic compound with neurotrophic activity, on cognitive performance and qEEG activity was investigated through a 12-week, open-label extension of a 4-week, randomised, placebo-controlled pilot study.
Summary · context
Thirty-three out of 41 patients with mild-to-moderate severe probable vascular dementia (VaD) according to NINDS-AIREN participating in the double-blind phase of the study were also assessed at the follow-up visit at week 16.
Report a problemFND-2092371201
02HumanRandomized controlled trialEfficacy outcome
In vascular dementia patients, Cerebrolysin 30 mL improved cognitive performance versus placebo at week 16 (p<0.05).
In plain wordsIn vascular dementia patients, Cerebrolysin 30 mL improved cognitive performance compared with placebo at week 16.
Peptide
Cerebrolysin
Outcome
IncreaseADAS-cog+ cognitive performance at week 16
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
30 mL · intravenous · 4 weeksAs given in this study (human).
Measurements
p value for ADAS-cog+ cognitive performance comparison
< 0.05
Cerebrolysin 30 mL versus placebo, week 16
Source sentences
Summary
At the week 16 follow-up visit, Cerebrolysin improved (p<0.05) cognitive performance at the 10-mL and 30-mL doses and reduced qEEG slowing significantly (p<0.05) at the 30-mL dose with respect to the placebo.
3 context sentences(design, population, supporting numbers)
Summary · context
The mean change in score from baseline in the ADAS-cog+ and the slow-to-fast qEEG power ratio (PR), used as an index of qEEG slowing, were the two primary endpoints.
Summary · context
The maintenance of the effects of Cerebrolysin, a peptidergic compound with neurotrophic activity, on cognitive performance and qEEG activity was investigated through a 12-week, open-label extension of a 4-week, randomised, placebo-controlled pilot study.
Summary · context
Thirty-three out of 41 patients with mild-to-moderate severe probable vascular dementia (VaD) according to NINDS-AIREN participating in the double-blind phase of the study were also assessed at the follow-up visit at week 16.
Report a problemFND-2092371202
03HumanRandomized controlled trialEfficacy outcome
In vascular dementia patients, Cerebrolysin 30 mL significantly reduced qEEG slowing versus placebo at week 16 (p<0.05).
In plain wordsIn vascular dementia patients, Cerebrolysin 30 mL reduced qEEG slowing compared with placebo at week 16.
Peptide
Cerebrolysin
Outcome
DecreaseqEEG slowing at week 16
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
30 mL · intravenous · 4 weeksAs given in this study (human).
Measurements
p value for qEEG slowing comparison
< 0.05
Cerebrolysin 30 mL versus placebo, week 16
Source sentences
Summary
At the week 16 follow-up visit, Cerebrolysin improved (p<0.05) cognitive performance at the 10-mL and 30-mL doses and reduced qEEG slowing significantly (p<0.05) at the 30-mL dose with respect to the placebo.
3 context sentences(design, population, supporting numbers)
Summary · context
The mean change in score from baseline in the ADAS-cog+ and the slow-to-fast qEEG power ratio (PR), used as an index of qEEG slowing, were the two primary endpoints.
Summary · context
The maintenance of the effects of Cerebrolysin, a peptidergic compound with neurotrophic activity, on cognitive performance and qEEG activity was investigated through a 12-week, open-label extension of a 4-week, randomised, placebo-controlled pilot study.
Summary · context
Thirty-three out of 41 patients with mild-to-moderate severe probable vascular dementia (VaD) according to NINDS-AIREN participating in the double-blind phase of the study were also assessed at the follow-up visit at week 16.
Report a problemFND-2092371203

Studies that did not test the peptide alone1

In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cerebrolysin.

04HumanNot a test of Cerebrolysin aloneRandomized controlled trialOther
In vascular dementia patients from the Cerebrolysin trial, changes in qEEG PR and ADAS-cog+ showed a significant positive correlation at week 16.
In plain wordsIn vascular dementia patients from the Cerebrolysin trial, qEEG PR changes were positively linked to ADAS-cog+ changes at week 16.
Peptide
Cerebrolysin
Outcome
Not applicableqEEG PR and ADAS-cog+ change correlation
Study
n = 33
Outcome group
Cognition and memory · Nervous system and cognition
Measurements
p value for qEEG PR and ADAS-cog+ change correlation
< 0.05
Correlation between changes from baseline in qEEG PR and ADAS-cog+, week 16
Source sentences
Summary
In addition, a significant (p<0.05) positive correlation between the change from the baseline qEEG PR and ADAS-cog+ variables was observed at week 16.
2 context sentences(design, population, supporting numbers)
Summary · context
The maintenance of the effects of Cerebrolysin, a peptidergic compound with neurotrophic activity, on cognitive performance and qEEG activity was investigated through a 12-week, open-label extension of a 4-week, randomised, placebo-controlled pilot study.
Summary · context
Thirty-three out of 41 patients with mild-to-moderate severe probable vascular dementia (VaD) according to NINDS-AIREN participating in the double-blind phase of the study were also assessed at the follow-up visit at week 16.
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Report a problemFND-2092371204

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.